Giving medical cannabis to infants is a difficult taboo to shift, but new research is paving the way. The launch of a clinical trial examining the use of CBD in newborns suffering from hypoxic ischemic encephalopathy (brain damage caused by lack of oxygen) means new hope for the million plus babies born each year with this condition.
Part of why doctors remain wary of cannabis medicine is the lack of randomized, double-blind, placebo controlled trials — the gold standard for medical research. Because of cannabis’ status as an illicit drug, research is often relegated to retrospective surveys, which are useful but more likely to be biased. But there are methods in between these two schemes, such as open-label trials.
Preventing nausea is a common medical use of cannabis. But nausea is a multi-faceted feeling. Motion sickness, morning sickness, the flu, or chemotherapy all cause slightly different versions of this discomfort.
Cannabinoids have been proposed for numerous neurodegenerative disorders. As a matter of fact, scientists employed by the US government filed a patent in 2001 for Cannabinoids as antioxidants and neuroprotectants, citing their potential for treating Alzheimer’s disease among others.
One of the only established harmful effects of CBD is the modulation of liver enzymes. High doses of CBD — a few hundred or thousand milligrams taken orally — can inhibit drug-metabolizing enzymes. Additionally, the elevation of aminotransferases (ALT and AST) is sometimes observed in patients taking CBD and valproate, an anti-epileptic drug. When these enzymes increase, it is usually indicative of ongoing stress on the liver and potential liver damage.